• Delfi Diagnostics Marries Fragmentomics, Machine Learning in Cancer Detection

  • Nov 21 2024
  • Durée: 58 min
  • Podcast

Delfi Diagnostics Marries Fragmentomics, Machine Learning in Cancer Detection

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • “Our mission is to make cancer less deadly through widely accessible next-generation early-detection blood tests.” Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Tousi joins BI analyst Jonathan Palmer to discuss the company’s fragment-based liquid biopsy technology and the immense opportunity to save lives through early cancer detection. Starting with lung cancer via its FirstLook test, Delfi expects to expand more broadly into other cancer types and applications like monitoring with a focus on access and affordability. The conversation touches on the company’s core values and the large opportunity set afforded by recent funding rounds.

    See omnystudio.com/listener for privacy information.
    Voir plus Voir moins
Voir plus Voir moins
activate_Holiday_promo_in_buybox_DT_T2

Ce que les auditeurs disent de Delfi Diagnostics Marries Fragmentomics, Machine Learning in Cancer Detection

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.